MiR-15/16 complex targets p70S6 kinase1 and controls cell proliferation in MDA-MB-231 breast cancer cells

Gene

Volumn 552, Issue 2, 2014, Pages 255-264

  Janaki Ramaiah, M ^a,c   Lavanya, A ^a   Honarpisheh, Mohsen ^a   Zarea, Mojtaba ^a   Bhadra, Utpal ^b   Bhadra, Manika Pal ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

^c SASTRA UNIVERSITY   (India)

Author keywords

MDA MB 231; MiR 15; MiR 16; MTOR; RPS6KB1

Indexed keywords

CASPASE 3; LENTIVIRUS VECTOR; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MICRORNA; MICRORNA 15; MICRORNA 16; P70S6 KINASE 1; PROTEIN P53; S6 KINASE; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN15 MICRORNA, HUMAN; MIRN16 MICRORNA, HUMAN; TARGET OF RAPAMYCIN KINASE;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CELL PROLIFERATION; CELL VIABILITY; CLONE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MICRORNAS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84908032627     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.09.052     Document Type: Article

References (51)

1. Akeno N., Miller A.L., Ma X., Wikenheiser-Brokamp K.A. p53 suppresses carcinoma progression by inhibiting mTOR pathway activation. Oncogene 2014, (Jan 27, Epub ahead of print). 10.1038/onc.2013.589.
2. Barlund M., Forozan F., Kononen J., Bubendorf L., Chen Y., Bittner M.L., Torhorst J., Haas P., Bucher C., Sauter G., Kallioniemi O.P., Kallioniemi A. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J. Natl. Cancer Inst. 2000, 92:1252-1259.
3. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 2004, 4(5):335-348.
4. Bonci D., Coppola V., Musumeci M., Addario A., Giuffrida R., Memeo L., D'Urso L., Pagliuca A., Biffoni M., Labbaye C., Bartucci M., Muto G., Peschle C., De Maria R. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 2008, 14:1271-1277.
5. Boominathan L. The tumor suppressors p53, p63 and p73 are regulators of microRNA processing complex. PLoS One 2010, 5:e10615.
6. Brosh R., Shalgi R., Liran A., Landan G., Korotayev K., Nguyen G.H., et al. p53-repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol. Syst. Biol. 2008, 4:229.
7. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(24):15524-15529.
8. Cheng A.M., Byrom M.W., Shelton J., Ford L.P. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005, 33:1290-1297.
9. Chung E.Y., Dews M., Cozma D., Yu D., Wentzel E.A., Chang T.C., Schelter J.M., Cleary M.A., Mendell J.T., Thomas-Tikhonenko A. c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster. Cancer Biol. Ther. 2008, 7:1758-1764.
10. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., Wojcik S.E., Aqeilan R.I., Zupo S., Dono M., Rassenti L., Alder H., Volinia S., Liu C.G., Kipps T.J., Negrini M., Croce C.M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:13944-13949.
11. Courjal F., Theillet C. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer Res. 1997, 57(19):4368-4377.
12. Czermin B., Melfi R., McCabe D., Seitz V., Imhof A., Pirrotta V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 2002, 111(2):185-196.
13. Druz A., Chen Y.C., Guha R., Betenbaugh M., Martin S.E., Shiloach J. Large-scale screening identifies a novel microRNA, miR-15a-3p, which induces apoptosis in human cancer cell lines. RNA Biol. 2013, 10(2):287-300.
14. Fabbri M., Bottoni A., Shimizu M., et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011, 305(1):59-67.
15. Fenton T.R., Gout I.T. Functions and regulation of the 70kDa ribosomal S6 kinases. Int. J. Biochem. Cell Biol. 2011, 43(1):47-59.
16. Fornari F., Milazzo M., Chieco P., Negrini M., Calin G.A., Grazi G.L., Pollutri D., Croce C.M., Bolondi L., Gramantieri L. miR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010, 70(12):5184-5193.
17. Gomes L.R., Terra L.F., Sogayar M.C., Labriola L. Epithelial-mesenchymal transition: implications in cancer progression and metastasis. Curr. Pharm. Biotechnol. 2011, 12(11):1881-1890.
18. Holz M.H., Blenis J. Identification of S6K1 as a novel mTOR-phosphorylating kinase. J. Biol. Chem. 2005, 280(28):26089-26093.
19. Hwang H.W., Mendell J.T. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br. J. Cancer 2006, 94:776-780.
20. Jiang B.H., Liu L.Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist. Updat. 2008, 11(3):63-76.
21. Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110:163-175.
22. Kim D., Akcakanat A., Singh G., Sharma C., Meric-Bernstam F. Regulation and localization of ribosomal protein S6 kinase1 isoforms. Growth Factors 2009, 27(1):12-21.
23. Klein U., Lia M., Crespo M., Siegel R., Shen Q., Mo T., et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010, 17(1):28-40.
24. Kogan-Sakin I., Tabach Y., Buganim Y., Molchadsky A., Solomon H., Madar S., Kamer I., Stambolsky P., Shelly A., Goldfinger N., Valsesia-wittmann S., Puisieux A., Zundelevich A., Gal-Yam E.N., Avivi C., Barshack I., Brait M., Sidransky D., Domany E., Rotter V. Mutant p53 (R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition immortalized prostate cells. Cell Death Differ. 2011, 18(2):271-281.
25. Lai K.P., Leong W.F., Chau J.F., Jia D., Zeng L., Liu H., He L., Hao A., Zhang H., Meek D., Velagapudi C., Habib S.L., Li B. S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response. EMBO J. 2010, 29(17):2994-3006.
26. Lerner M., Harada M., Loven J., Castro J., Davis Z., Oscier D., Henriksson M., Sangfelt O., Grander D., Corcoran M.M. DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp. Cell Res. 2009, 315:2941-2952.
27. Li P.D., Zhang W.J., Zhang M.Y., Yuan L.J., Cha Y.L., Ying X.F., Wu G., Wang H.Y. Over expression of RPS6KB1 predicts worse prognosis in primary HCC patients. Med. Oncol. 2012, 29(5):3070-3076.
28. Linsley P.S., Schelter J., Burchard J., Kibukawa M., Martin M.M., Bartz S.R., Johnson J.M., Cummins J.M., Raymond C.K., Dai H., Chau N., Cleary M., Jackson A.L., Carleton M., Lim L. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol. Cell. Biol. 2007, 27(6):2240-2252.
29. Magnuson B., Ekim B., Fingar D.C. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem. J. 2012, 441(1):1-21.
30. Malouf G.G., Taube J.H., Lu Y., Roysarkar T., Panjarian S., Estecio M.R., Jelinek J., Yamazaki J., Raynal N.J., Long H., Tahara T., Tinnirello A., Ramachandran P., Zhang X.Y., Liang S., Mani S.A., Issa J.P. Architecture of epigenetic reprogramming following Twist1 mediated epithelial-mesenchymal transition. Genome Biol. 2013, 14(12):R144. (Epub ahead of print, 24367927. 5).
31. Maruani D.M., Spiegel T.N., Harris E.N., Shachter A.S., Unger H.A., Herrero-González S., Holz M.K. Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation. Oncogene 2012, 31(49):5073-5080.
32. Merkel O., Asslaber D., Piñón J.D., Egle A., Greil R. Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. Cell Cycle 2010, 9(14):2764-2768.
33. Nagaraja A.K., Creighton C.J., Yu Z., Zhu H., Gunaratne P.H., Reid J.G., Olokpa E., Itamochi H., Ueno N.T., Hawkins S.M., Anderson M.L., Matzuk M.M. A link between miR-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol. Endocrinol. 2010, 24(2):447-463.
34. Noh W.C., Kim Y.H., Kim M.S., Koh J.S., Kim H.A., Moon N.M., Paik N.S. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res. Treat. 2008, 110(3):477-483.
35. Ofir M., Hacohen D., Ginsberg D. miR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E. Mol. Cancer Res. 2011, 9(4):440-447.
36. Polager S., Ginsberg D. p53 and E2f: partners in life and death. Nat. Rev. Cancer 2009, 9:738-748.
37. Polytarchou C., Iliopoulos D., Struhl K. An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(36):14470-14475.
38. Porrello E.R., Johnson B.A., Aurora A.B., Simpson E., Nam Y.J., Matkovich S.J., et al. miR-15 family regulates postnatal mitotic arrest of cardiomyocytes. Circ. Res. 2011, 109(6):670-679.
39. Santra M.K., Wajapeyee N., Green M.R. F-Box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature 2009, 459(4):722-726.
40. Sridharan S., Basu A. S6 kinase 2 promotes breast cancer cell survival via Akt. Cancer Res. 2011, 71(7):2590-2599.
41. Sun D.F., Zhang Y.J., Tian X.G., Chen Y.X., Fang J.Y. Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation. Cell Biol. Int. 2014, 38(1):50-63.
42. Suzuki H.I., Yamagata K., Sugimoto K., Iwamoto T., Kato S., Miyazono K. Modulation of microRNA processing by p53. Nature 2009, 460:529-533.
43. Vander Hage J.A., van den Broek L.J., Legrand C., Clahsen P.C., Bosch C.J., Robanus-Maandag E.C., van de Velde C.J., van de Vijver M.J. Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br. J. Cancer 2004, 90(8):1543-1550.
44. Wang F., Fu X.D., Zhou Y., Zhang Y. Down-regulation of the cyclin E1 oncogene expression by microRNA-16-1 induces cell cycle arrest in human cancer cells. BMB Rep. 2009, 142:725-730.
45. Wei S., Wang H., Lu C., Malmut S., Zhang J., Ren S., Yu G., Wang W., Tang D.D., Yan C. Activating transcription factor 3 suppresses the oncogenic function of mutant p53. J. Biol. Chem. 2014, 289(13):8947-8959.
46. Wu K.J., Yang M.H. Epithelial-mesenchymal transition and cancer stemness: the Twist1-Bmi1 connection. Biosci. Rep. 2011, 31(6):449-455.
47. Xie J., Proud C.G. Crosstalk between mTOR complexes. Nat. Cell Biol. 2013, 15(11):1263-1265.
48. Xu-Monette Z.Y., Medeiros L.J., Li Y., Orlowski R.Z., Andreeff M., Bueso-Ramos C.E., Greiner T.C., McDonnell T.J., Young K.H. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 2012, 119(16):3668-3683.
49. Yang Q., Inoki K., Ikenoue T., Guan K.L. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 2006, 20(20):2820-2832.
50. Zhang Y., Ni H.J., Cheng D.Y. Prognostic value of phosphorylated mTOR/RPS6KB1 in non-small cell lung cancer. Asian Pac. J. Cancer Prev. 2013, 14(6):3725-3728.
51. Zhao X.F., Zhao M.Y., Chai L., Kukuruga D., Tan M., Stass S.A. Amplified RPS6KB1 and CDC2 genes are potential biomarkers for aggressive HIV+/EBV+ diffuse large B-cell lymphomas. Int. J. Clin. Exp. Pathol. 2013, 6(2):148-154.